Safety and efficacy of 0.6 mg/kg rt-PA: Optimum rt-PA dose revisited

Annals of the New York Academy of Sciences

Volumn 1268, Issue 1, 2012, Pages 108-112

  Mori, Etsuro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute ischemic stroke; Alteplase; Optimum dose; Recombinant tissue plasminogen activator; Thrombolytic therapy

Indexed keywords

ALTEPLASE; DUTEPLASE;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ETHNIC GROUP; FIBRINOLYSIS; HUMAN; JAPAN; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; OPTIMAL DRUG DOSE; POPULATION; TREATMENT OUTCOME;

EID: 84866526494     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06689.x     Document Type: Article

References (20)

1. Mori, E. et al 1992. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976-982.
2. Yamaguchi, T., T. Hayakawa & H. Kiuchi 1993. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc. Dis. 3: 269-272.
3. Yamaguchi, T., T. Hayakawa & H. Kiuchi 1995. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T. et al ., eds.: 223-229. Springer-Verlag. Tokyo
4. Yamaguchi, T. et al 2006. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37: 1810-1815.
5. Yamaguchi, T. et al Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Supplemental Appendix 2. Available at: http://stroke.ahajournals.org/content/37/7/1810.long#sec-8
6. Ueshima, S. et al 2002. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb. Haemost. 87: 544-546.
7. Brott, T.G. et al 1992. Urgent therapy for stroke. Part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23: 632-640.
8. Haley, E.C. Jr. et al 1992. Urgent therapy for stroke. Part II: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23: 641-645.
9. Kimura, K. et al 2004. Analysis of 16922 patients with acute ischemic stroke and transient ischemic attack in Japan. Cerebrovasc. Dis. 18: 47-56.
10. Mori, E. et al 2010. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 41: 461-465.
11. Hirano, T. et al 2010. Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients: exploratory analysis of the Japan Alteplase Clinical Trial II. Stroke 41: 2828-2833.
12. Nakagawara, J. et al 2010. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41: 1984-1989.
13. Wahlgren, N. et al 2007. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369: 275-282.
14. Chao, A.C. et al 2011. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 42: 1658-1864.
15. Wang, Y. et al 2010. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). J. Clin. Neurosci. 17: 988-992.
16. Zhou, X.Y. et al 2011. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. Int. J. Stroke 6: 523-530.
17. Sharma, V.K. et al 2011. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int. J. Stroke 6: 523-530.
18. Mori, E. & J-ACT II Group. 2010. Response to letter by Ng and Sharma. Stroke 41: e547-e548.
19. Haley, E.C. Jr. et al 1993. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 24: 1000-1004.
20. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333: 1581-1587.